Mendelian randomization

RP Raha Pazoki
MV Marijana Vujkovic
JE Joshua Elliott
EE Evangelos Evangelou
DG Dipender Gill
MG Mohsen Ghanbari
PM Peter J. van der Most
RP Rui Climaco Pinto
MW Matthias Wielscher
MF Matthias Farlik
VZ Verena Zuber
RK Robert J. de Knegt
HS Harold Snieder
AU André G. Uitterlinden
JL Julie A. Lynch
XJ Xiyun Jiang
SS Saredo Said
DK David E. Kaplan
KL Kyung Min Lee
MS Marina Serper
RC Rotonya M. Carr
PT Philip S. Tsao
SA Stephen R. Atkinson
AD Abbas Dehghan
IT Ioanna Tzoulaki
MI M. Arfan Ikram
KH Karl-Heinz Herzig
MJ Marjo-Riitta Järvelin
BA Behrooz Z. Alizadeh
CO Christopher J. O’Donnell
DS Danish Saleheen
BV Benjamin F. Voight
KC Kyong-Mi Chang
MT Mark R. Thursz
PE Paul Elliott
request Request a Protocol
ask Ask a question
Favorite

To further investigate the effect of circulating levels of the liver enzymes on the risk of cardiovascular outcomes, a two-sample MR approach was employed54. We considered the outcomes of CHD, ischemic stroke, and intracerebral hemorrhage (ICH). Genetic association estimates on outcomes were obtained from the CARDIoGRAMplusC4D Consortium for CHD (60,801 cases and 123,504 controls, multiethnic)55, the MEGASTROKE Consortium for ischemic stroke (60,341 cases and 454,450 controls, multiethnic)56, and the International Stroke Genetic Consortium for ICH (1545 cases and 1481 controls, European ancestry)57. For the main analysis, the random-effects IVW meta-analysis MR approach was used, with the simple and weighted median, and MR-Egger approaches also employed as sensitivity analyses as these are more robust to the inclusion of potentially pleiotropic variants58.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A